Rebamipide versus Diquafosol et Cyclosporine pour le syndrome de l'œil sec périopératoire dans la chirurgie de la cataracte
Rebamipide contre Diquafosol-Cyclosporine pour la Maladie des Yeux Secs Périopératoire dans la Chirurgie de la Cataracte : Un Essai Randomisé
The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.
The main questions it aims to answer are:
Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?
Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.
Participants will:
Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.
Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.
Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Dry eye disease (DED) is common in patients undergoing cataract surgery and may worsen during the perioperative period, leading to ocular discomfort and delayed visual recovery. Pharmacologic treatments targeting tear film instability and ocular surface inflammation are therefore important in perioperative management.
This prospective, randomized, parallel-group clinical trial compared two perioperative treatment strategies for DED in patients scheduled for cataract surgery. Eligible participants with pre-existing dry eye disease were randomized in a 1:1 ratio to receive either topical rebamipide 2% monotherapy or combination therapy with topical diquafosol 3% and cyclosporine 0.05%. Study medications were initiated 1 month prior to surgery and continued for 3 months postoperatively.
The primary outcome measure was the change in tear film breakup time (TBUT) during the early postoperative period. Secondary outcome measures included changes in corneal staining graded by the Oxford scale, patient-reported symptoms assessed by the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, and ocular surface inflammation evaluated using a tear matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay.
Clinical assessments were performed at baseline, on the day of surgery, and at postoperative week 1, month 1, and month 3. Safety was evaluated by monitoring intraoperative and postoperative adverse events throughout the study period.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Seoul
-
Seoul, Seoul, Corée du Sud
- Samsung Medical Center
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Adults scheduled for cataract surgery
-
Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:
- Tear film breakup time (TBUT) ≤7 seconds
- Oxford corneal staining grade ≥1
- Schirmer's test value ≤10 mm/5 min
-
Ability and willingness to comply with the study protocol and follow-up schedule
-
Provision of written informed consent
Exclusion Criteria:
- Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
- Use of topical intraocular pressure-lowering medications
- History of ocular surgery other than cataract surgery in the study eye
- Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Group R
Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily |
|
Comparateur actif: Group DC
Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively. |
Topical administration, four times daily Topical administration, two times daily |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Tear Film Breakup Time (TBUT)
Délai: From baseline to postoperative week 1
|
Change in tear film breakup time (TBUT) from baseline and during the early postoperative period following cataract surgery, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. |
From baseline to postoperative week 1
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Ocular Surface Disease Index (OSDI) Score
Délai: From baseline to 1 and 3 months postoperatively
|
Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes). |
From baseline to 1 and 3 months postoperatively
|
|
Change in Corneal Staining Grade (Oxford Scale)
Délai: From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes). |
From baseline to postoperative week 1, and to 1 and 3 months postoperatively
|
|
Change in Schirmer's Test Value
Délai: From baseline to 1 and 3 months postoperatively
|
Change in tear secretion measured by Schirmer's test without anesthesia, comparing tear production between rebamipide monotherapy and diquafosol-cyclosporine combination therapy. |
From baseline to 1 and 3 months postoperatively
|
|
Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level
Délai: From baseline to 1 and 3 months postoperatively
|
Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a point-of-care immunoassay (InflammaDry), comparing ocular surface inflammation between treatment groups. |
From baseline to 1 and 3 months postoperatively
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies oculaires
- Maladies de l'appareil lacrymal
- Maladies du cristallin
- Cataracte
- Syndromes de sécheresse oculaire
- Solutions pharmaceutiques
- Peptides
- Acides aminés, peptides et protéines
- Préparations pharmaceutiques
- Actions pharmacologiques
- Actions et utilisations chimiques
- Utilisations thérapeutiques
- Composés polycycliques
- Solutions
- Utilisations spéciales de produits chimiques
- Composés macrocycliques
- Peptides, cyclique
- Cyclosporines
- Cyclosporine
- Solutions ophtalmiques
- rebamipide
- diquafosol
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- SMC RVK Trial I
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .